LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Harmony Biosciences To Participate In Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$33.22 0.22 0.67

PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:

Wells Fargo 2024 Healthcare Conference

  • Location: Boston
  • Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET

2024 Cantor Global Healthcare Conference

  • Location: New York City
  • Fireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ET

A webcast of the fireside chats will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
This email address is being protected from spambots. You need JavaScript enabled to view it.

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB